289042-10-0

Basic information

• Product Name: N-[5-(Diphenylphosphinoylmethyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl]-N-methylmethanesulfonamide
• Synonyms: N-[5-(Diphenyl-phosphinoylmethyl)-4-(4-fluoro-phenyl)-6-isopropyl-pyrimidin-2-yl]-N-methyl-methanesulfonamide;Rosuvastatin Intermediates ZD9;Methanesulfonamide, N-[5-[(diphenylphosphinyl)methyl]-4-(4-fluorophenyl)-6-(1-methylethyl)-2-pyrimidinyl]-N-methyl;4-(4-fluorophenyl)-6-isopropyl-2-[(n-methyl-n-methylsulfonyl)amino] pyriminl-5-yl- phosphine oxide;Triphenyl[4-(4-fluorophenyl)-6-isopropyl-2-[(2-n-methyl-n-methylsulfonyl)amino]pyrimidine-5-yl-methyl]phosphine bromine;Diphenyl [4-(4-fluorophenyl)- 6-isopropyl-2-[(n-Methyl- n-ethylsulfonyl)aMino] pyriMidine-5-yl- ethyl]phosphine;Diphenyl[4-(4-fluorophenyl)-6-isopropyl-2-[(2-n-Methyl-n-Methylsulfonyl)aMino]pyriMidine-5-yl-Methyl]phosphine oxide;Diphenyl[4-(4-Fluorophenyl)-6-isopropyl-2-(N-MethylMethylsulfonyl)aMino-pyriMidin-5-yl-Methyl]phosphine Oxide
• CAS NO: 289042-10-0
• Molecular Formula: C₂₈H₂₉FN₃O₃PS
• Molecular Weight: 537.59
• EINECS: 1806241-263-5
• Product Categories: Rosuvastatin intermediates
• Mol File: 289042-10-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 679.125 °C at 760 mmHg
• Flash Point: 364.522 °C
• Appearance: /
• Density: 1.322 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.625
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Chloroform (Slightly), DMSO (Slightly)
• PKA: -0.57±0.10(Predicted)
• CAS DataBase Reference: N-[5-(Diphenylphosphinoylmethyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl]-N-methylmethanesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[5-(Diphenylphosphinoylmethyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl]-N-methylmethanesulfonamide(289042-10-0)
• EPA Substance Registry System: N-[5-(Diphenylphosphinoylmethyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl]-N-methylmethanesulfonamide(289042-10-0)

Safety Data

• Hazardous Substances Data: 289042-10-0(Hazardous Substances Data)

Usage

Uses

An intermediate in the production of Rosuvastatin (R700500) derivatives.

InChI:InChI=1/C28H29FN3O3PS/c1-20(2)26-25(19-36(33,23-11-7-5-8-12-23)24-13-9-6-10-14-24)27(21-15-17-22(29)18-16-21)31-28(30-26)32(3)37(4,34)35/h5-18,20H,19H2,1-4H3

Upstream product

• 4020-99-9 diphenylphosphinous acid methyl ester 
• 147118-36-3 N-[4-(4-fluorophenyl)-5-(hydroxymethyl)-6-(propan-2-yl)pyrimidin-2-yl]-N-methylmethanesulfonamide 
• 925422-06-6 N-[5-chloromethyl-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-2-yl]-N-methyl-methanesulfonamide 
• 147118-30-7 ethyl 2-(N-methyl-N-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-carboxylic acid 
• 289042-11-1 methyl 4-(4-fluorophenyl)-6-isopropyl-2-(N-methanesulphonyl-N-methylamino)pyrimidine-5-carboxylate 
• 719-80-2 Ethyl diphenylphosphinite 
• 1079-66-9 chloro-diphenylphosphine 
• 799842-07-2 N-[5-(bromomethyl)-4-(4-fluorophenyl)-6-(propan-2-yl)pyrimidin-2-yl]-N-methylmethanesulfonamide 
• 147118-37-4 N-[4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl]-N-methylmethanesulfonamide 

Downstream Products

• 289042-12-2 2-[(4R,6S)-6-[(E)-2-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(isopropyl)pyrimidin-5-yl]vinyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid tert butyl ester 
• 503610-43-3 Rosuvastatin lactone 
• 1353637-14-5 E-(7-{2-(N-methyl-N-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-yl}-[(3R,5S)-3,5-dihydroxy-hept-6-enoic acid])-N-methoxy-N-methyl-amide 
• 1353637-13-4 E-(6-{2-[2-(N-methyl-N-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-yl]vinyl}-[(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl])-N-methoxy-N-methyl-acetamide 
• 1378943-63-5 C₂₉H₄₀FN₃O₆S 
• 287714-41-4 rosuvastatin 
• 862994-56-7 E-7-[2-(N-methyl-N-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid diisopropylamine salt 
• 851440-18-1 6-((1E)-2-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methylsulfonyl)amino)pyrimidin-5-yl)ethenyl)-2,2-dimethyl-1,3-dioxan-4yl acetic acid ethyl ester 
• 808162-99-4 isopropyl 2-[(4R,6S)-6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl]vinyl}-2,2-dimethyl-1,3-dioxan-4-yl]acetate 

Relevant articles and documents

A method for preparing a rosuvastatin calcium intermediate

The invention relates to the technical field of pharmaceutical chemistry, particularly the field of process optimization and cost control for pharmaceutical intermediate preparation, and more particularly relates to an impurity in preparation of a rosuvastatin calcium intermediate and a method for synthesizing the intermediate from the impurity. A compound I' is reacted with ozone and a reductantto obtain a compound IV and an important intermediate III, the compound IV is further subjected to reduction and substitution to prepare another intermediate II important in preparation of the rosuvastatin calcium intermediate, and the compound II and the compound III are adopted to prepare an intermediate compound I. Through recovery and utilization of the impurity compound I', the preparation cost of the compound I is significantly reduced. The method is simple in process and suitable for industrial large-scale production.

PROCESS FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF

The present invention provides an improved process for preparing HMG-CoA reductase inhibitors such as rosuvasatin calcium, fluvastatin sodium, and pitavastatin calcium under a mild condition, using a novel amide-bond-containing compound having R2-N-O-R1 moiety as a key intermediate. And also, the present invention provides the novel compound, an intermediate useful for the preparation thereof, and a process for the preparation thereof.

PROCESS FOR THE PREPARATION OF PYRIMIDINE DERIVATIVES

There is described a process for the preparation of compounds of formula (1) starting from the reaction of the compounds of formulae (24), (25) and (26) to form the compound of formula (23), wherein in each case R1, R2 and R3 are each independently of the others an unsubstituted or substituted organic radical; R4 is hydrogen, unsubstituted or substituted C1-C8alkyl, C1-C8alkoxy, phenoxy or benzyloxy, or halogen; Y1 and Y2 are each independently of the other hydrogen or a protecting group, or Y1 and Y2 together are a protecting bridge; and X1 is hydrogen, an organic radical or a cation; and also novel intermediates.